## **List of abbreviations**

ALT Alanine aminotransferase

AMA Anti-mitochondrial antibody

ANA Antinuclear antibody

Anti-dsDNA Anti-double stranded DNA

Anti-HCV Hepatitis C virus antibody

Anti-LKM-1 Anti-liver kidney microsomal type 1

Anti-LKM-2 Anti-liver kidney microsomal type 2

Anti-LKM-3 Anti-liver kidney microsomal type 3

Anti-RNP Anti-ribonucleoprotein

ASMA Antismooth muscle antibody

AST Aspartate aminotransferase

CAH Chronic active hepatitis

CENP-A Centromere protein A

CLD Chronic liver disease

CRP C-reactive protein

CTD Connective tissue diseases

CTL Cytotoxic T cell

CTM (-) C COBAS TaqMan negative control

CYP 2C9 Cytochrome P450 2C9

CYP 2D6 Cytochrome oxidase P450 2D6

DNA Deoxyribonucleic acid

EB Elution buffer

EIA Enzyme immunoassay

ELISA Enzyme-linked immunoabsorbant assay

ENA Extractable nuclear antigens

ESR Erythrocyte sedimentation rate

FITC Fluorescein iso-thiocyanate conjugate

HAV Hepatitis A virus

HBsAg Hepatitis B surface antigen

HBV Hepatitis B virus

HCV Hepatitis C virus

HCV H (+) C HCV high positive control

HCV QS HCV quantitation standard

HCV L(+)C HCV low positive control

HDV Hepatitis D virus

HEV Hepatitis E virus

HFV Hepatitis F virus

HGV Hepatitis G virus

HIV Human immunodeficiency virus

HS. Highly significant (P<0.01)

IFN Interferon

IgA Immunoglobulin A

IgG Immunoglobulin G

IgM Immunoglobulin M

IVD In vitro diagnostics

LCR Ligase chain reaction

LD Lactate dehydrogenase

LKMA Liver kidney microsomal antibody

MC Mixed cryoglobulinemia

MDH Malate dehydrogenase

MGP Magnetic glass particles

NASBA Nucleic acid sequence-based amplification

NK cell Natural killer cell

NS. Non-significant (P>0.05)

OR Odds ratio

ORDAC Over-range dilution and correction

PBC Primary biliary cirrhosis

PBS Phosphate buffer saline

PCR Polymerase chain reaction

PEG-IFN Pegylated interferon

PG WR COBAS AmpliPrep/COBAS TaqMan wash

reagent

RF Rheumatoid factor

RIBA Recombinant antigen immunoblot assay

RNA Ribonucleic acid

RRR Relative risk ratio

S. Significant (P<0.05)

SDA Strand displacement amplification

SLE Systemic lupus erythematosus

SPU Sample processing unit

SVR Sustained virologic response

TMA Transcription-mediated amplification

TTV Transfusion transmitted virus

## **List of symbols**

μl Microliter

IU/L International Units per Liter

ml Milliliter

mmol/L Millimoles per Liter

°C The degree Celsius

# List of tables

Table No.	Title	Page
Table(1):	Descriptive statistics of AST values in three groups.	39
Table(2):	Descriptive statistics of ALT values in three groups.	40
Table(3):	Correlation coefficient between different parameters in PEG-IFN groups.	41
<b>Table (4):</b>	Correlation coefficient between different parameters in liver support groups.	43
<b>Table (5):</b>	Positivity of autoantibodies and Cryoglobulins in PEG-IFN group in comparison to control group (non-viral hepatitis patients).	44
Table(6):	Positivity of autoantibodies and cryoglobulins in liver support group in comparison to control group (non-viral hepatitis patients).	45
Table(7):	Positivity of autoantibodies and Cryoglobulins in PEG-IFN group in comparison to liver Support group.	46
<b>Table (8):</b>	Distribution of autoantibodies in three studied groups.	47
Table (9):	Relative risk ratio (RRR).	48

# **List of figures**

Fig. No.	Title	
Fig.(1):	Comparison between control group, liver support group and PEG-IFN group as regards AST values.	39
Fig. (2):	Comparison between control group, liver support group and PEG-IFN group as regards ALT values.	40
Fig. (3):	Linear regression analysis showing positive correlation between AST values and ALT values among PEG-IFN group.	41
Fig. (4):	Linear regression analysis showing negative correlation between AST values and HCV RNA values among PEG-IFN group.	42
Fig. (5):	Linear regression analysis showing negative correlation between AST values and PEG-IFN dose among PEG-IFN group.	42
Fig. (6):	Linear regression analysis showing positive correlation between AST values and ALT values among Liver support group.	43
Fig.(7):	Positivity of autoantibodies and Cryoglobulins in PEG-IFN group in comparison to control group.	44

Fig.(8):	Positivity of autoantibodies and Cryoglobulins in liver support group in comparison to control group.	45
Fig.(9):	Positivity of autoantibodies and Cryoglobulins in PEG-IFN group in comparison to liver Support group.	46
Fig.(10):	Distribution of autoantibodies in three studied groups.	47



Arts, Science and Education
Botany Department

# Evaluation of autoantibodies in chronic hepatitis C Egyptian patients

A Thesis Submitted in Partial Fulfillment for the Requirements of the Master Degree in Science

(Microbiology)

#### BY

### Aliaa Mohamed Seif Elden Abd Elkader

BSC. Microbiology, 2006

### Supervised by

#### Late Dr. Sohair Abdel-Aziz Mostafa

Prof. of Microbiology, Botany Department, Faculty of Women for Art, Science and Education, Ain Shams University

#### Dr. Zeinab Mohamed Hassan kheiralla

Prof. of Microbiology, Botany Department, Faculty of Women for Art, Science and Education, Ain Shams University

## Dr. Mohga Abd El Fatah Ebrahim


Consultant of Clinical Pathology, Ain Shams University Specialized Hospital


#### Dr. Shimaa Mohamed Abd El Salam

Lecturer of Microbiology, Botany Department, Faculty of Women for Arts, Science and Education, Ain Shams University

Botany Department
Faculty of Women for Arts, Science and Education, Ain Shams
University
(2014)







# **Contents**

Subjects	
• List of tables	1
• List of figures	II
• Introduction	IV
• Aim of work	V
• Abstract	VI
I. Review of literature	1
Hepatitis viruses	1
1.1 Hepatitis A	1
1.2 Hepatitis B	2
1.3 Hepatitis D	
1.4 Hepatitis E	
1.5 Hepatitis of unknown etiology	
1.5.1 Hepatitis F	
1.5.2 Hepatitis G	
1.5.3Transfusion Transmitted virus	5
2. Hepatitis C virus	

2.1Routes of transmission of hepatitis C	
2.2 Natural history and clinical features	7
2.3Laboratory diagnosis of hepatitis C	9
2.4Treatment	10
3. Autoimmunity and autoantibodies	16
3.1Antinuclear antibody	18
3.2Smooth muscle antibody	19
3.3Mitochondrial antibody	20
3.4Antiparital cell antibody	20
3.5Liver kidney microsomal antibody	22
3.6Cryoglobulins	22
II. Subjects and Methods	24
1.Liver function tests	26
2.Detection of HCV viremia using (PCR)	28
3.Detection of autoantibodies	
4. Cryoglobulins test	
Statistical analysis	